65 related articles for article (PubMed ID: 2387312)
1. Reevaluation of the C3a active site using short synthetic C3a analogues.
Köhl J; Casaretto M; Gier M; Karwath G; Gietz C; Bautsch W; Saunders D; Bitter-Suermann D
Eur J Immunol; 1990 Jul; 20(7):1463-8. PubMed ID: 2387312
[TBL] [Abstract][Full Text] [Related]
2. Design and biological activity of a new generation of synthetic C3a analogues by combination of peptidic and non-peptidic elements.
Gerardy-Schahn R; Ambrosius D; Casaretto M; Grötzinger J; Saunders D; Wollmer A; Brandenburg D; Bitter-Suermann D
Biochem J; 1988 Oct; 255(1):209-16. PubMed ID: 3264156
[TBL] [Abstract][Full Text] [Related]
3. Functional activities of synthetic anaphylatoxic peptides in widely used biological assays.
Kola A; Klos A; Bautsch W; Kretzschmar T; Köhl J
Clin Exp Immunol; 1992 May; 88(2):368-72. PubMed ID: 1572104
[TBL] [Abstract][Full Text] [Related]
4. Synthetic peptides as antagonists of the anaphylatoxin C3a.
Kretzschmar T; Pohl M; Casaretto M; Przewosny M; Bautsch W; Klos A; Saunders D; Köhl J
Eur J Biochem; 1992 Nov; 210(1):185-91. PubMed ID: 1446671
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the C-terminal C5a effector site with short synthetic C5a analog peptides.
Köhl J; Lübbers B; Klos A; Bautsch W; Casaretto M
Eur J Immunol; 1993 Mar; 23(3):646-52. PubMed ID: 8383599
[TBL] [Abstract][Full Text] [Related]
6. Characterization of C3a receptor-proteins on guinea pig platelets and human polymorphonuclear leukocytes.
Gerardy-Schahn R; Ambrosius D; Saunders D; Casaretto M; Mittler C; Karwarth G; Görgen S; Bitter-Suermann D
Eur J Immunol; 1989 Jun; 19(6):1095-102. PubMed ID: 2666143
[TBL] [Abstract][Full Text] [Related]
7. Designing synthetic superagonists of C3a anaphylatoxin.
Ember JA; Johansen NL; Hugli TE
Biochemistry; 1991 Apr; 30(15):3603-12. PubMed ID: 2015217
[TBL] [Abstract][Full Text] [Related]
8. C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets.
Zanker B; Rasokat H; Hadding U; Bitter-Suermann D
Agents Actions Suppl; 1982; 11():147-57. PubMed ID: 6983827
[TBL] [Abstract][Full Text] [Related]
9. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
[TBL] [Abstract][Full Text] [Related]
10. A mechanism of action for anaphylatoxin C3a stimulation of mast cells.
Mousli M; Hugli TE; Landry Y; Bronner C
J Immunol; 1992 Apr; 148(8):2456-61. PubMed ID: 1373170
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning of two isoforms of the guinea pig C3a anaphylatoxin receptor: alternative splicing in the large extracellular loop.
Fukuoka Y; Ember JA; Hugli TE
J Immunol; 1998 Sep; 161(6):2977-84. PubMed ID: 9743361
[TBL] [Abstract][Full Text] [Related]
12. Peptide analogues of the anaphylatoxin C3a; syntheses and properties.
Ambrosius D; Casaretto M; Gerardy-Schahn R; Saunders D; Brandenburg D; Zahn H
Biol Chem Hoppe Seyler; 1989 Mar; 370(3):217-27. PubMed ID: 2713103
[TBL] [Abstract][Full Text] [Related]
13. Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach.
Pasupuleti M; Walse B; Svensson B; Malmsten M; Schmidtchen A
Biochemistry; 2008 Sep; 47(35):9057-70. PubMed ID: 18690701
[TBL] [Abstract][Full Text] [Related]
14. Synthetic C3a analogs as specific inhibitors of C3a activity.
Meuer S; Hadding U; Andreatta R; Bitter-Suermann D
Immunopharmacology; 1981 Sep; 3(3):275-80. PubMed ID: 6975766
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of a specific C3a receptor on guinea pig platelets.
Fukuoka Y; Hugli TE
J Immunol; 1988 May; 140(10):3496-501. PubMed ID: 3283237
[TBL] [Abstract][Full Text] [Related]
16. Enhanced biopotency of synthetic C3a analogues by membrane binding. A fluorescence anisotropy decay study.
Federwisch M; Casaretto M; Gerardy-Schahn R; Bitter-Suermann D; Wollmer A
Biophys Chem; 1992 Oct; 44(3):151-61. PubMed ID: 1420945
[TBL] [Abstract][Full Text] [Related]
17. Cyclic disulfide analogues of the complement component C3a. Synthesis and conformational investigations.
Pohl M; Ambrosius D; Grötzinger J; Kretzschmar T; Saunders D; Wollmer A; Brandenburg D; Bitter-Suermann D; Höcker H
Int J Pept Protein Res; 1993 Apr; 41(4):362-75. PubMed ID: 8496018
[TBL] [Abstract][Full Text] [Related]
18. Suppression of humoral immune responses by synthetic C3a peptides.
Morgan EL; Weigle WO; Erickson BW; Fok KF; Hugli TE
J Immunol; 1983 Nov; 131(5):2258-61. PubMed ID: 6355293
[TBL] [Abstract][Full Text] [Related]
19. Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a(desArg) with a transient release of calcium via a pertussis toxin-sensitive signal transduction pathway.
Zwirner J; Götze O; Moser A; Sieber A; Begemann G; Kapp A; Elsner J; Werfel T
Eur J Immunol; 1997 Sep; 27(9):2317-22. PubMed ID: 9341775
[TBL] [Abstract][Full Text] [Related]
20. Biologic activity of synthetic analogues of C5a anaphylatoxin.
Ember JA; Sanderson SD; Taylor SM; Kawahara M; Hugli TE
J Immunol; 1992 May; 148(10):3165-73. PubMed ID: 1578141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
